Bifogade filer
Kurs
-5,32%
Kalender
| Est. tid* | ||
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2023-11-23 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-30 | - | Årsstämma |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2023-02-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-24 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2022-05-19 | - | Årsstämma |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-16 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-17 | - | Årsstämma |
| 2021-05-27 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2021-05-07 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-15 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-19 | - | Extra Bolagsstämma 2019 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-31 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2019-05-29 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-30 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-14 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2018-06-13 | - | Årsstämma |
| 2018-05-31 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-11-28 | - | Kvartalsrapport 2017-Q3 |
| 2017-11-15 | - | Extra Bolagsstämma 2017 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-09 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2017-06-08 | - | Årsstämma |
| 2017-05-31 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-20 | - | Bokslutskommuniké 2016 |
| 2016-11-30 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-01 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2016-05-31 | - | Årsstämma |
| 2016-05-31 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-29 | - | Bokslutskommuniké 2015 |
| 2016-01-21 | - | Extra Bolagsstämma 2016 |
| 2015-11-30 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-31 | - | Kvartalsrapport 2015-Q2 |
| 2015-06-12 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2015-06-11 | - | Årsstämma |
| 2015-05-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-27 | - | Bokslutskommuniké 2014 |
| 2014-11-28 | - | Kvartalsrapport 2014-Q3 |
| 2014-09-12 | - | Extra Bolagsstämma 2014 |
| 2014-08-29 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-10 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2014-06-09 | - | Årsstämma |
| 2014-05-23 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-05 | - | Bokslutskommuniké 2013 |
| 2013-11-29 | - | Kvartalsrapport 2013-Q3 |
| 2013-09-04 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-31 | - | Kvartalsrapport 2013-Q1 |
| 2013-05-08 | - | Split RLS 10:1 |
| 2013-04-11 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2013-04-10 | - | Årsstämma |
| 2013-03-05 | - | Bokslutskommuniké 2012 |
| 2012-11-26 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-31 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-12 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
| 2012-06-11 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
- Net sales amounted to TSEK 198 (TSEK 132).
- Earnings before interest and taxes (EBIT) amounted to MSEK -5,2 (MSEK 6,2).
- Earnings per share after dilution at SEK -0,07 (SEK 0,09).
- Cash flow from operating activities amounted to TSEK -5 114 (TSEK -6 214).
- Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4).
- Equity ratio was 77 % (86 %).
- Net sales amounted to TSEK 904 (TSEK 472).
- Earnings before interest and taxes (EBIT) amounted to MSEK -16,4 (MSEK 3,98).
- Earnings per share after dilution at SEK -0,23 (SEK 0,06).
- Cash flow from operating activities amounted to MSEK -12,7 (MSEK -3,46).
- Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4).
- Equity ratio was 77 % (86 %).
- RLS issues new shares by way of set-off, totaling TSEK 10 000.
- An article regarding ChloraSolv is published in Journal of Wound Care.
- New CEO Björn Larsson starts October 1.
- RLS has raised liquid assets through a new issue in November 2022 (rights issue) of MSEK 29.4.
- The Swedish Medicines Agency has approved RLS' application for pressure ulcers.
- RLS visits the conference Wounds UK in Harrogate, England.
The Interim Report Q3, 2022, is enclosed and is also available here (https://rls.global/financial-information/financial-reports-eng/).
Publication
This information was submitted for publication through the agency of the below contact person,at 08.00 CET on November 24, 2022.
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17[th] May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. During the period 2012-2017, the company was listed on Aktietorget.
FOR MORE INFORMATION, PLEASE CONTACT:
Björn Larsson, CEO, RLS Global
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25
Eva Jagenheim, CFO, RLS Global
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57